Viking Therapeutics (VKTX) drew fresh attention on 15 November 2026 after presenting new VK2735 obesity data at ObesityWeek. The Phase 2 VENTURE analysis linked weekly injections to BMI category shifts and cardiometabolic marker changes.
VKTX has been busy on the conference circuit in November, and that steady drumbeat around obesity data appears to be feeding into short term momentum, with a 1 month share price return of 16.09% and a 7 day move of 8.87% pushing the stock to US$29.22. This comes even though the 1 year total shareholder return is down 25.29%, while the 3 and 5 year total shareholder returns, at roughly 1.6x and over 4x respectively, point to a story that has already been very powerful for long term holders.
Scan other obesity and metabolic plays that show similar clinical or share price energy with a curated list of 38 healthcare AI stocks that tie drug development to advanced data and AI tools.
The VK2735 buzz and a US$29 handle on Viking Therapeutics reset the conversation fast. Do the clinical headlines still leave enough upside in the risk side of that trade for new money?
Against a last close of $29.22, the bullish analyst Narrative on Simply Wall St anchors Viking Therapeutics at a fair value of $125. That gap reflects optimistic assumptions about how VK2735 and the broader obesity pipeline could translate into future earnings, using a 7.54% discount rate.
The initiation of two 68 week Phase III SUNRISE trials for oral VK2735, using daily doses across a wide range and targeting both obesity with comorbidities and obesity with type 2 diabetes, gives Viking Therapeutics a path to segment the market by formulation and indication. This can support incremental revenue streams and operating leverage.
See why 4 investors see Viking Therapeutics as 77% undervalued.
Result: Fair Value of $125 (UNDERVALUED)
Still, the bullish Viking Therapeutics story could unravel quickly if VK2735 or VK3019 stumble in trials, or if cash burn forces heavy, earnings-dilutive fundraising.
Find out about the key risks to this Viking Therapeutics narrative.
The bullish fair value of $125 for Viking Therapeutics leans heavily on analyst forecasts. A very different picture comes from the SWS DCF model, which estimates future cash flow value at just $3.16 per share, far below the $29.22 market price and pointing to an overvalued stock on this framework. That sort of gap forces a simple question for any VKTX holder: which story feels more realistic to you?
For a closer look at how this cash flow view is built and where the key sensitivities sit, Look into how the SWS DCF model arrives at its fair value..
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Viking Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 35 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Obesity buzz or valuation gap, either way the Viking Therapeutics debate is moving fast and rewards investors who focus on the numbers. Act quickly, stress test the bullish and cautious cases side by side, and make sure you understand the 3 important warning signs.
If you only focus on Viking Therapeutics, you risk missing other setups that fit your style, your risk tolerance, and your timeline just as well.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com